

Orofacial Swelling and Elevated Fecal Calprotectin Levels in a Patient with Melkersson-Rosenthal Syndrome

Cavallaro Giulia^{1,2}, Guida Agostino³, D'Aniello Tiziana², Lionello Francesco², Ronga Ilaria², Zampa Giorgia², Vestini Rosanna², Cavallaro Raimondo^{2*}, Ferrara Luigi² and Bova Maria²

¹Faculty of Medicine, University of Campania "Luigi Vanvitelli", Italy

²Division of Internal Medicine 2, Department of Medicine and Medical Specialties, A. Cardarelli Hospital, Naples, Italy

³Division of Dentistry, A Cardarelli Hospital, Naples, Italy

*Corresponding author

Cavallaro Raimondo, Division of Internal Medicine 2, Department of Medicine and Medical Specialties, A. Cardarelli Hospital, Naples, Italy.

Received: November 02, 2025; **Accepted:** November 10, 2025; **Published:** November 20, 2025

Background: Melkersson-Rosenthal syndrome (MRS) is a rare, inherited neurocutaneous syndrome characterised by a triad of clinical features: recurrent facial nerve palsy, persistent or recurrent orofacial swelling, fissured tongue. These three clinical entities can be present all together or not (complete or incomplete forms).

Sometimes MRS may be associated with Crohn's disease or sarcoidosis.

Case History: A 25-year-old male presented with recurrent acute abdominal pain, persistent upper lip edema and a history of allergic rhinitis and bronchial asthma. Intraoral examination revealed a fissured tongue. Oral mucosa biopsy demonstrated non-caseating granulomas. Fecal calprotectin test depicted elevated levels. Complete abdominal ultrasound and Magnetic Resonance Enterography (MRE) were performed but did not highlight anything significant. Other systemic granulomatous diseases were excluded.

The patient was treated with oral corticosteroid with partial and transient benefit. Then intralesional treatment with triamcinolone was administered, with good results.

The patient was advised to repeat calprotectin dosage after some months, in order to exclude or confirm the hypothesis of a secondary form of facial granulomatosis.

Discussion: MRS is a rare neurocutaneous disease. MRS diagnosis and treatment are difficult due to its rarity and unclear etiology.

Early recognition of MRS can reduce diagnostic delays, which often lead to suboptimal patient outcomes, and facilitate appropriate management.

Copyright: ©2025 Cavallaro Raimondo, et al. This an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.